JNJ-40411813
JNJ-40411813 is a pharmaceutical drug with 7 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
3
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
7 of 7 finished
0.0%
0 ended early
0
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy
A Study of JNJ-40411813 in Healthy Japanese Male Participants
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia
Ketamine Challenge Study With JNJ-40411813
Clinical Trials (7)
A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy
A Study of JNJ-40411813 in Healthy Japanese Male Participants
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia
Ketamine Challenge Study With JNJ-40411813
A Study to Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of JNJ-404118413 in Healthy Male Patients
A Dose-Ranging Study of JNJ-40411813 in Healthy Male Volunteers
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7